Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Intensive Care
Published in: Annals of Intensive Care 1/2016

Open Access 01-12-2016 | Review

Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient

Authors: Matteo Bassetti, Charles-Edouard Luyt, David P. Nicolau, Jérôme Pugin

Published in: Annals of Intensive Care | Issue 1/2016

Login to get access

Abstract

Gram-negative pneumonia in patients who are intubated and mechanically ventilated is associated with increased morbidity and mortality as well as higher healthcare costs compared with those who do not have the disease. Intravenous antibiotics are currently the standard of care for pneumonia; however, increasing rates of multidrug resistance and limited penetration of some classes of antimicrobials into the lungs reduce the effectiveness of this treatment option, and current clinical cure rates are variable, while recurrence rates remain high. Inhaled antibiotics may have the potential to improve outcomes in this patient population, but their use is currently restricted by a lack of specifically formulated solutions for inhalation and a limited number of devices designed for the nebulization of antibiotics. In this article, we review the challenges clinicians face in the treatment of pneumonia and discuss the characteristics that would constitute an ideal inhaled drug/device combination. We also review inhaled antibiotic options currently in development for the treatment of pneumonia in patients who are intubated and mechanically ventilated.
Literature
1.
American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA). Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.CrossRef
2.
3.
Melsen WG, Rovers MM, Groenwold RHH, Bergmans DCJJ, Camus C, Bauer TT, Hanisch EW, Klarin B, Koeman M, Krueger WA, Lacherade JC, Lorente L, Memish ZA, Morrow LE, Nardi G, van Nieuwenhoven CA CA, O’Keefe GE, George Nakos G, Scannapieco FA, Seguin P, Staudinger T, Topeli A, Ferrer M, Bonten MJM. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13:665–71.CrossRefPubMed
4.
5.
Luna C, Aruj P, Niederman M, Garzón J, Violi D, Prignoni A, Ríos F, Baquero S, Gando S. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J. 2006;27:158–64.CrossRefPubMed
6.
Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008;36:1089–96.CrossRefPubMed
7.
Jenkins S, Fisher A, Peterson J, Nicholson S, Kaniga K. Meta-analysis of doripenem vs comparators in patients with Pseudomonas infections enrolled in four phase III efficacy and safety clinical trials. Curr Med Res Opin. 2009;25:3029–36.CrossRefPubMed
8.
Kollef M, Chastre J, Clavel M, Restrepo M, Michiels B, Kaniga K, Cirillo I, Kimko H, Redman R. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care. 2012;16:R218.CrossRefPubMedPubMedCentral
9.
Awad SS, Rodriguez AH, Chuang YC, Marjanek Z, Pareigis AJ, Reis G, Scheeren TWL, Sánchez AS, Zhou X, Saulay M, Engelhardt M. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014;59:51–61.CrossRefPubMedPubMedCentral
10.
Flume P, VanDevanter D. Clinical applications of pulmonary delivery of antibiotics. Adv Drug Deliv Rev. 2015;85:1–6.CrossRefPubMed
11.
Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case–control study. Respir Ther. 2001;29:2303–9.
12.
Boucher H, Talbot G, Bradley J, Edwards J, Gilbert D, Rice L, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12.CrossRefPubMed
13.
Spellberg B, Bartlett J, Wunderink R, Gilbert DN. Novel approaches are needed to develop tomorrow’s antibacterial therapies. Am J Respir Crit Care Med. 2015;191:135–40.CrossRefPubMedPubMedCentral
14.
Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F, Nicolau DP, Paiva JA, Tumbarello M, Welte T, Wilcox M, Zahar RJ, Poulakou G. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med. 2015;41:776–95.CrossRefPubMed
15.
Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J. 1999;14:221–9.CrossRefPubMed
16.
17.
Cruciana M, Gatti G, Lazzarini L, Furlan G, Broccali G, Malena M, Franchini C, Concia E. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother. 1996;38:865–9.CrossRef
18.
Imberti R, Cusato M, Villani P, Carnevale L, Iotti G, Langer M, Regazzi M. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest. 2010;138:1333–9.CrossRefPubMed
19.
Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Int Med J. 2011;41:441–9.CrossRef
20.
Arnold A, Brouse S, Pitcher W, Hall R. Empiric therapy for Gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind. J Intensive Care Med. 2010;25:259–70.CrossRefPubMed
21.
Smith B, Yogaratnam D, Levasseur-Franklin K, Forni A, Fong J. Introduction to drug pharmacokinetics in the critically ill patient. Chest. 2012;141:1327–36.CrossRefPubMed
22.
Blot S, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient—concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11.CrossRefPubMed
23.
Vinks A, Derendorf H, Mouton J. Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics. New York/Heidelberg/Dordrecht/London: Springer; 2014. p. 63–72.CrossRef
24.
Palmer LB. Aerosolized antibiotics in the intensive care unit. Clinics Chest Med. 2011;32:559–74.CrossRef
25.
Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, Golmard J, Rouby J. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology. 2012;117:1335–47.CrossRefPubMed
26.
Le J, Neuhauser M, Brown J, Gentry C, Klepser M, Marr A, Schiller D, Schwiesow J, Tice S, VandenBussche H, Wood C. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Pharmacotherapy. 2010;30:562–84.CrossRefPubMed
27.
Wood C. Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia. Exp Rev Anti-Infect Ther. 2011;9:993–1000.CrossRef
28.
Luyt C-E, Combes A, Nieszkowska A, Trouillet J, Chastre J. Aerosolized antibiotics to treat ventilator-associated pneumonia. Curr Opin Infect Dis. 2009;22:154–8.CrossRefPubMed
29.
Abu-Salah T, Dhand R. Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update. Adv Ther. 2011;29:728–47.CrossRef
30.
Goldstein I, Wallet F, Robert J, Bequemin M, Marquette C, Rouby J. Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med. 2002;165:171–5.CrossRefPubMed
31.
Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette C-H, Rouby J-J, the Experimental Intensive Care Unit Study Group. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med. 2002;166:1375–81.CrossRefPubMed
32.
Badia J, Soy D, Adrover M, Ferrer M, Sarasa M, Alarcón A, Codina C, Torres A. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother. 2004;54:508–14.CrossRefPubMed
33.
Luyt C-E, Clavel M, Guntupalli K, Johannigman J, Kennedy J, Wood C, Corkery K, Gribben D, Chastre J. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care. 2009;13:R200.CrossRefPubMedPubMedCentral
34.
Cooney G, Lum B, Tomaselli M, Fiel S. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. Clin Pharmacol. 1994;34:255–9.CrossRef
35.
Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby JJ, the Nebulized Antibiotics Study Group. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011;184:106–15.CrossRefPubMed
36.
Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir Care. 2007;52:866–84.PubMed
37.
38.
Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, Wentz K, Smith AL. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993;328:1740–6.CrossRefPubMed
39.
Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis. 1999;179:1190–6.CrossRefPubMed
40.
Palmer LB, Smaldone GC. Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med. 2014;189:1225–33.CrossRefPubMed
41.
Niederman M, Chastre J, Corkery K, Fink J, Luyt C-E, Sanchez Garcia M. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 2012;38:263–71.CrossRefPubMed
42.
Chastre J, Luyt C-E. Optimising the duration of antibiotic therapy for ventilator-associated pneumonia. Eur Respir Rev. 2007;16:40–4.CrossRef
43.
Fihman V, Messika J, Hajage D, Tournier V, Gaudry S, Magdoud F, Barnaud G, Billard-Pomares T, Branger C, Dreyfuss D, Ricard JD. Five-year trends for ventilator-associated pneumonia: correlation between microbiological findings and antimicrobial drug consumption. Int J Antimicrob Agents. 2015;46:518–25.CrossRefPubMed
44.
Niederman M, Chastre J, Corkery K, Marcantonio A, Fink J, Luyt C-E, Sanchez M and The Amikacin Study Group. NKTR-061 (inhaled amikacin) reduces intravenous antibiotic use in intubated mechanically ventilated patients during treatment of Gram-negative pneumonia. ATS 18–23 May 2007, Poster A326.
45.
46.
47.
48.
49.
50.
Zampieri F, Nassar A Jr, Gusmao-Flores D, Taniguchi L, Torres A, Ranzani O. Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care. 2015;19:150.CrossRefPubMedPubMedCentral
51.
Rouby J, Bouhemad B, Monsel A, Brisson H, Arbelot C, Lu Q, the Nebulized Antibiotic Study Group. Aerosolized antibiotics for ventilator-associated pneumonia: lessons from experimental studies. Anesthesiology. 2012;117:1364–80.CrossRefPubMed
52.
53.
Dhand R. Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J Aerosol Med Pulm Drug Deliv. 2008;21:45–60.CrossRefPubMed
54.
Kadrichu N, Boc S, Corkery K, Challoner P. In vitro efficiency of the Amikacin Inhale System, a novel integrated drug-device delivery system. ISICEM, 19–22 March 2013, Poster A384.
55.
Laube B, Janssens H, de Jongh F, Devadason S, Dhand R, Diot P, Everard M, Horvath I, Navalesi P, Voshaar T, Chrystyn H. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37:1308–31.CrossRefPubMed
56.
Dhand R. Maximising aerosol delivery during mechanical ventilation: go with the flow and go slow. Intensive Care Med. 2003;29:1041–2.CrossRefPubMed
57.
Miller D, Amin M, Palmer L, Shah A, Smaldone G. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med. 2003;168:1205–9.CrossRefPubMed
58.
Restrepo R, Walsh B. Humidification during invasive and noninvasive mechanical ventilation: 2012. Respir Care. 2012;57:782–8.CrossRefPubMed
59.
Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F, Becquemin M, Le Naour G, Marquette C, Rouby J. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med. 2010;36:1147–55.CrossRefPubMed
60.
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72.CrossRefPubMed
61.
Masterton RG, Galloway A, French G, Street M, Armstrong E, Brown E, Cleverley J, Dilworth P, Fry C, Gascoigne AD, Knox A, Nathwani D, Spencer R, Wilcox M. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the Working Party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2008;62:5–34.CrossRefPubMed
62.
Ehrmann S, Roche-Campo F, Sferrazza Papa G, Isabey D, Brochard L, Apiou-Sbirlea G, REVA research network. Aerosol therapy during mechanical ventilation: an international survey. Intensive Care Med. 2013;39:1048–56.CrossRefPubMed
63.
64.
Montgomery A, Rhomberg P, Abuan T, Walters K, Flamm R. Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics. Antimicrob Agents Chemother. 2014;58:3707–13.
65.
Montgomery A, Rhomberg P, Abuan T, Walters K, Flamm R. Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens. Antimicrob Agents Chemother. 2014;58:3714–9.CrossRefPubMedPubMedCentral
66.
Montgomery A, Vallance S, Abuan T, Tservistas M, Davies A. A randomized double-blind placebo-controlled dose-escalation Phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI Investigational eFlow® Inline Nebulizer System in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv. 2014;27:441–8.CrossRefPubMedPubMedCentral
67.
Hallal A, Cohn S, Namias N, Habib F, Baracco G, Manning R, Crookes B, Schulman C. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect (Larchmt). 2007;8:73–81.CrossRef
68.
Kadrichu N, Corkery K, Dang T, Challoner P. Performance of amikacin inhale: impact of supplemental oxygen and device orientation. Crit Care. 2015;19(Suppl 1):P120.CrossRefPubMedCentral
69.
Kadrichu N, Boc S, Corkery K and Challoner P. Influence of humidification on in vitro dose delivery for Amikacin Inhale by mechanical ventilation. ESICM, 27 September–1 October 2014, Abstract 0867.
70.
Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med. 2001;14(Suppl 1):19–26.CrossRef
71.
72.
73.
Seemann S, Schmitt A, Waldner R, Hug M, Knoch M. Improving aerosol drug delivery in CF therapy. European Cystic Fibrosis Conference, 22–26 June 2005, Poster P113.
Metadata
Title
Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient
Authors
Matteo Bassetti
Charles-Edouard Luyt
David P. Nicolau
Jérôme Pugin
Publication date
01-12-2016
Publisher
Springer Paris
Published in
Annals of Intensive Care / Issue 1/2016
Electronic ISSN: 2110-5820
DOI
https://doi.org/10.1186/s13613-016-0140-x

Other articles of this Issue 1/2016

Annals of Intensive Care 1/2016 Go to the issue

Research

Association of REL polymorphisms and outcome of patients with septic shock

Research

Unsuspected serotonin toxicity in the ICU

Research

Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study

Research

Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial

Research

Can we improve transthoracic echocardiography training in non-cardiologist residents? Experience of two training programs in the intensive care unit

Research

Vitamin D deficiency and length of pediatric intensive care unit stay: a prospective observational study